ICX Intercytex

 

TIDMICX 
 
RNS Number : 5867S 
Intercytex Group plc 
20 May 2009 
 

20 May 2009 
 
 
Result of AGM 
 
 
Intercytex Group plc (AIM: ICX) ("Intercytex"), a developer of regenerative 
medicine products, confirms that at the General Meeting held earlier today, all 
the Resolutions, set out in the Notice of General Meeting included in the Annual 
Report sent to shareholders on 27 April 2009, were duly passed. 
- Ends - 
 
 
Enquiries 
 
 
For more information, contact: 
 
 
+---------------------------------------------+-----------------+ 
| Intercytex Group plc                        |                 | 
+---------------------------------------------+-----------------+ 
| Nick Higgins, Chief Executive Officer       | Tel: 0161 904   | 
|                                             | 4500            | 
+---------------------------------------------+-----------------+ 
| Max Herrmann, Chief Financial Officer       |                 | 
+---------------------------------------------+-----------------+ 
|                                             |                 | 
+---------------------------------------------+-----------------+ 
| Financial Dynamics                          |                 | 
+---------------------------------------------+-----------------+ 
| Jonathan Birt                               | Tel: 0207 269   | 
|                                             | 7205            | 
+---------------------------------------------+-----------------+ 
| Emma Thompson                               | Tel: 0207 269   | 
|                                             | 7267            | 
+---------------------------------------------+-----------------+ 
|                                             |                 | 
+---------------------------------------------+-----------------+ 
| Piper Jaffray Ltd                           |                 | 
+---------------------------------------------+-----------------+ 
| Will Carnwath                               | Tel: 0203 142   | 
|                                             | 8700            | 
+---------------------------------------------+-----------------+ 
 
 
 
 
Notes for Editors 
Intercytex is a regenerative medicine company developing innovative products to 
restore skin and hair. Intercytex is using its fully integrated cell technology 
platform to develop products that harness the innate ability of human cells to 
regenerate and repair the body. 
Intercytex has four products in development: 
  *  VAVELTA , a skin repair and rejuvenation product intended to improve the feel, 
  function and appearance of skin damaged by scarring and the aging process, and 
  available from a number of accredited centres in the UK 
  *  SHEF-1, development of a stem cell line suitable for differentiation into RPE 
  cells, being carried out in collaboration with the London Project to Cure 
  Blindness 
  *  ICX-TRC, a hair regeneration product. Phase II trial completed 
  *  ICX-SKN, being developed as a skin graft replacement for burns and acute wounds, 
  Phase I trials completed 
 
Intercytex commenced operations in 2000 and currently employs around 50 staff. 
In addition to its head office in Cambridge, UK, it has GMP compliant clinical 
production facility plus research and development laboratories in Manchester, 
UK. Additional laboratories are located in Boston, US and Sheffield, UK. 
Intercytex' shares trade on the Alternative Investment Market of the London 
Stock Exchange under the ticker symbol ICX.L. 
Additional information on the Company can be found at www.intercytex.com 
 
 
Statements contained within this press release may contain forward-looking 
information or statements with respect to the financial condition, results of 
operations and business achievements/performance of Intercytex and certain of 
the plans and objectives of management of Intercytex with respect thereto. By 
their nature, forward-looking statements involve risks and uncertainties that 
may cause actual results to vary from those contained in the forward-looking 
statements. In some cases, you can identify such forward-looking statements by 
terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 
'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or 
similar expressions.  A number of factors, including the satisfactory progress 
of research and development, could cause Intercytex' actual financial condition, 
results of operations and business achievements/performance to differ materially 
from the estimates made or implied in such forward-looking statements and, 
accordingly, reliance should not be placed on such statements. Forward 
projections reflect management's best estimates based on information available 
at the time of issue and are not a guarantee of future performance. Other than 
as required by applicable law, Intercytex does not undertake any obligation to 
update or revise any forward-looking information or statements to reflect events 
or circumstances after the date of this release. 
 
 
The term "Intercytex" refers to Intercytex Group plc and its subsidiary 
undertakings. 
Dealing disclosure requirements 
Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, 
"interested" (directly or indirectly) in 1% or more of any class of "relevant 
securities" of Intercytex, all "dealings" in any "relevant securities" of 
Intercytex (including by means of an option in respect of, or a derivative 
referenced to, any such "relevant securities") must be publicly disclosed by no 
later than 3.30pm (London time) on the Business Day following the date of the 
relevant transaction.  This requirement will continue until the Scheme becomes 
effective or the offer lapses or is otherwise withdrawn or the date on which the 
"offer period" otherwise ends.  If two or more persons act together pursuant to 
an agreement or understanding, whether formal or informal, to acquire an 
"interest" in "relevant securities" of Intercytex, they will be deemed to be a 
single person for the purpose of Rule 8.3 of the City Code. 
Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant 
securities" of Intercytex by Intercytex or its "associates" must be disclosed by 
no later than 12.00 noon (London time) on the Business Day following the date of 
the relevant transaction. 
A disclosure table, giving details of the companies in whose "relevant 
securities" "dealings" should be disclosed, and the number of such securities in 
issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. 
"Interests in securities" arise, in summary, when a person has long economic 
exposure, whether conditional or absolute, to changes in the price of 
securities.  In particular, a person will be treated as having an "interest" by 
virtue of the "ownership" or control of securities, or by virtue of any option 
in respect of, or derivative referenced to, securities. 
Terms in quotation marks are defined in the City Code, which can also be found 
on the Panel's website.  If you are in any doubt as to whether or not you are 
required to disclose a  "dealing" under Rule 8, you should consult the Panel. 
Rule 2.10 
In accordance with Rule 2.10 of the Code, Intercytex confirms that it has 
97,166,497 ordinary shares in issue and admitted to trading on the AIM market of 
the London Stock Exchange plc under the ISIN GB 00B0762609. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RAGSEDFDSSUSEDI 
 

Intercytex (LSE:ICX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Intercytex (LSE:ICX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024